Greenwich LifeSciences, Inc. (GLSI)

NASDAQ: GLSI · IEX Real-Time Price · USD
8.84
+0.06 (0.68%)
At close: Sep 29, 2023, 4:00 PM
8.66
-0.18 (-2.04%)
After-hours: Sep 29, 2023, 4:09 PM EDT
0.68%
Market Cap 113.58M
Revenue (ttm) n/a
Net Income (ttm) -8.86M
Shares Out 12.85M
EPS (ttm) -0.70
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 8,815
Open 8.73
Previous Close 8.78
Day's Range 8.60 - 8.85
52-Week Range 8.19 - 21.50
Beta 3.14
Analysts Strong Buy
Price Target 38.00 (+329.86%)
Earnings Date Nov 13, 2023

About GLSI

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is h... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Sep 25, 2020
Employees 3
Stock Exchange NASDAQ
Ticker Symbol GLSI
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for GLSI stock is "Strong Buy" and the 12-month stock price forecast is $38.0.

Price Target
$38.0
(329.86% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Greenwich LifeSciences Provides Year End Update

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to ...

9 months ago - Business Wire

Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2023

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to ...

10 months ago - Business Wire

Greenwich LifeSciences Announces Activation of Clinical Sites and Commencement of Phase III Clinical Trial

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Announces Activation of Clinical Sites and Commencement of Phase III Clinical Trial

1 year ago - Business Wire

Greenwich LifeSciences Provides Updates on Flamingo-01 Phase III Clinical Trial

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Provides Updates on Flamingo-01 Phase III Clinical Trial

1 year ago - Business Wire

Greenwich LifeSciences Provides Financing Strategy & Corporate Update

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Provides Financing Strategy & Corporate Update

1 year ago - Business Wire

Here's Why Greenwich Lifesciences Shares Are Popping Off Today

Greenwich Lifesciences Inc (NASDAQ: GLSI) shares are trading higher by 32.95% to $11.46 Tuesday afternoon after the FDA removed the clinical hold on the company's Flamingo-01 Phase 3 trial of GP2. Gre...

1 year ago - Benzinga

Greenwich LifeSciences Announces Removal of Clinical Hold Permitting Phase III Clinical Trial to Proceed

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Announces Removal of Clinical Hold Permitting Phase III Clinical Trial to Proceed

1 year ago - Business Wire

Greenwich LifeSciences Announces Suspension of Share Repurchase Program

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Announces Suspension of Share Repurchase Program

1 year ago - Business Wire

Greenwich LifeSciences to Resume Stock Repurchase Program

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences to Resume Stock Repurchase Program

1 year ago - Business Wire

Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial & ASCO Meeting

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial & ASCO Meeting

1 year ago - Business Wire

Greenwich LifeSciences to Participate in Upcoming Jefferies, Wainwright, ASCO and BIO International Conferences

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences to Participate in Upcoming Jefferies, Wainwright, ASCO and BIO International Conferences

1 year ago - Business Wire

Greenwich LifeSciences Presents Phase IIb Data, Published at AACR 2022, Further Supporting the Role of GP2 in Preventing Metastatic Breast Cancer

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Presents Phase IIb Data, Published at AACR 2022, Further Supporting the Role of GP2 in Preventing Metastatic Breast Cancer

1 year ago - Business Wire

Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial, Patent Filings, & AACR Meeting

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial, Patent Filings, & AACR Meeting

1 year ago - Business Wire

Greenwich LifeSciences to Present at 2022 BIO CEO & Investor Conference

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences to Present at 2022 BIO CEO & Investor Conference

1 year ago - Business Wire

Greenwich LifeSciences Provides Update on Upcoming Phase III Clinical Trial, FLAMINGO-01

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Provides Update on Upcoming Phase III Clinical Trial, FLAMINGO-01

1 year ago - Business Wire

Greenwich LifeSciences to Implement Stock Repurchase Program for up to $10 Million & to Extend Lock-up of Insiders for an Additional 1 Year

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences to Implement Stock Repurchase Program for up to $10 Million & to Extend Lock-up of Insiders for an Additional 1 Year

1 year ago - Business Wire

Greenwich LifeSciences CEO Participates in TD Ameritrade Interview to Discuss 2021 SABCS Poster

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences CEO Participates in TD Ameritrade Interview to Discuss 2021 SABCS Poster

1 year ago - Business Wire

Greenwich LifeSciences Reveals 5-Year Data for GP2 Immunotherapy In Breast Cancer Settings

Greenwich LifeSciences Inc (NASDAQ: GLSI) has published new GP2 Phase 2b trial data. The trial enrolled HER2 positive patients, who received a standard course of trastuzumab after surgery, and HER2 lo...

1 year ago - Benzinga

Greenwich LifeSciences Announces Presentation of 5 Year Data for GP2 Phase IIb Clinical Trial, Revealing Potential For New T Cell Platform Technology

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Announces Presentation of 5 Year Data for GP2 Phase IIb Clinical Trial, Revealing Potential For New T Cell Platform Technology

1 year ago - Business Wire

Greenwich LifeSciences to Participate in Multiple Interviews and Conferences

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences to Participate in Multiple Interviews and Conferences

1 year ago - Business Wire

Greenwich LifeSciences Expands Role of Industry Expert Dr. F. Joseph Daugherty to Include Medical Monitor for its Upcoming Phase III Clinical Trial

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Expands Role of Industry Expert Dr. F. Joseph Daugherty to Include Medical Monitor for its Upcoming Phase III Clinical Trial

1 year ago - Business Wire

Greenwich LifeSciences Announces Commencement of the First Commercial Line Filling of GP2

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Announces Commencement of the First Commercial Line Filling of GP2

1 year ago - Business Wire

Greenwich LifeSciences CEO Interview to Air on Bloomberg U.S. on the RedChip Money Report

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences CEO Interview to Air on Bloomberg U.S. on the RedChip Money Report

2 years ago - Business Wire

Greenwich LifeSciences to Participate in Jefferies' 12th Annual London Healthcare Conference

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences to Participate in Jefferies' 12th Annual London Healthcare Conference

2 years ago - Business Wire

Greenwich LifeSciences Announces Acceptance of Two Posters at Upcoming 2021 SABCS Breast Cancer Conference

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Announces Acceptance of Two Posters at Upcoming 2021 SABCS Breast Cancer Conference

2 years ago - Business Wire